Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

GSK PLC (GSK)

958 + Investors. Track Smart Money conviction in GSK. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +100
Streak
4Q ▲
Buyers last Q
54%

Smart Money Signals — GSK

Based on 940 hedge funds · latest filing: 2025 Q4 · updated quarterly

📈

Buying streak — 4 quarters in a row

last 6Q
For 4 consecutive quarters, more hedge funds added GSK than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
940 hedge funds hold GSK right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
📶

Steady growth — +19% more funds vs a year ago

fund count last 6Q
+149 new funds entered over the past year (+19% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction.
🟡

Slight buying edge — 54% buying

471 buying396 selling
Last quarter: 471 funds bought or added vs 396 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
📈

More new buyers each quarter (+71 vs last Q)

new funds entering per quarter
Funds opening a new GSK position: 91 → 109 → 100 → 171. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.
🔒

68% of holders stayed for 2+ years

■ 68% conviction (2yr+) ■ 16% medium ■ 17% new
635 out of 940 hedge funds have held GSK for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
📈

Growing discovery — still being found

91 → 91 → 109 → 100 → 171 new funds/Q
New funds entering each quarter: 91 → 109 → 100 → 171. A growing number of institutions are discovering GSK each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.
🏛️

Deep conviction — 71% of holders stayed 2+ years

■ 71% veterans ■ 9% 1-2yr ■ 20% new
Of 958 current holders: 677 (71%) have held for over 2 years without selling. These are not momentum buyers — they have lived through drawdowns and stayed. A large veteran base acts as a stabilizing force during selloffs.
🏆

Elite ownership — 64% AUM from top-100 funds

64% from top-100 AUM funds
34 of 940 holders are among the 100 largest funds by AUM, controlling 64% of total institutional value in GSK. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.
3.6
out of 10
Low Exit Risk
Exit risk score 3.6/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Hedge Fund Ownership: GSK

How many hedge funds hold GSK — quarterly history vs. share price
Quarterly hedge fund ownership of GSK vs. share price

Market Analysis: GSK

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: GSK

-- --
Smart Money Signal ?
Broad Consensus, Selective Conviction

Many quality funds hold this stock, but top-tier positions remain relatively small.

68 top-rated funds 3 high-conviction
Consensus
8.0
/ 10
breadth
×
Elite
4.8
/ 10
conviction
Hedge Fund Positioning: GSK
2026 Q1 Stats Unlock in 22 days 958 + Investors

Track Smart Money conviction in GSK. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2025 Q4) Prior (2025 Q3) Change
Funds Holding 958 863 11.01%
13F Shares 401M 391M 2.63%
Total Value $18.71B $20.22B -7.47%
New Positions 171 100 +71
Increased Positions 328 354 -26
Closed Positions 72 94 -22
Reduced Positions 349 324 +25
Total Calls 14 16 -12.5%
Total Puts 9 15 -40.0%
PUT/CALL Ratio 0.64 0.94 Bullish

Statistics: GSK

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

958 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in GSK. Verified SEC 13F-HR filings.

Top 25 institutional holders of GSK — 2025 Q4 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Clean Yield Group 2.52% 161,978 $8.9M
2 MILLER HOWARD INVESTMENTS INC /NY 2.46% 1,629,351 $89.9M
3 KEATING INVESTMENT COUNSELORS INC 2.39% 175,168 $9.7M
4 TWIN CITY PRIVATE WEALTH, LLC 1.88% 44,445 $2.5M
5 CHRISTINE MESSMER PC 1.75% 49,718 $2.7M
6 Stockman Wealth Management, Inc. 1.65% 270,147 $14.9M
7 Foster Victor Wealth Advisors, LLC 1.33% 394,595 $23.4M
8 TrueMark Investments, LLC 1.24% 115,322 $6.4M
9 Roberts Wealth Advisors, LLC 1.20% 85,476 $4.7M
10 FIGURE 8 INVESTMENT STRATEGIES LLC 1.09% 20,306 $1.1M
11 Yelin Lapidot Holdings Management Ltd. 1.02% 88,500 $4.9M
12 Gilman Hill Asset Management, LLC 1.01% 121,175 $6.7M
13 Yoffe Investment Management, LLC 0.97% 13,657 $754K
14 Sound Income Strategies, LLC 0.92% 340,474 $19.1M
15 Old Port Advisors 0.87% 68,665 $3.8M
16 BONNESS ENTERPRISES INC 0.84% 41,480 $2.3M
17 TOWER TRUST & INVESTMENT Co 0.83% 23,007 $1.3M
18 Argent Advisors, Inc. 0.80% 53,310 $2.9M
19 Douglas Lane & Associates, LLC 0.80% 1,009,401 $55.7M
20 TruWealth Advisors, LLC 0.71% 269,102 $14.9M
21 Stanley-Laman Group, Ltd. 0.71% 105,176 $5.8M
22 InvesTrust 0.69% 29,785 $1.6M
23 ARS Wealth Advisors Group, LLC 0.59% 127,516 $7.0M
24 Verity Asset Management, Inc. 0.57% 24,730 $1.4M
25 CITIZENS & NORTHERN CORP 0.55% 40,036 $2.2M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — GSK PLC (GSK)

What does the Smart Money Trend signal show for GSK?

Buying streak — 4 quarters in a row: For 4 consecutive quarters, more hedge funds added GSK than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for GSK?

Slight buying edge — 54% buying: Last quarter: 471 funds bought or added vs 396 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for GSK holders?

Elite ownership — 64% AUM from top-100 funds: 34 of 940 holders are among the 100 largest funds by AUM, controlling 64% of total institutional value in GSK. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held GSK?

68% of holders stayed for 2+ years: 635 out of 940 hedge funds have held GSK for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.